Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.54 |
| ▸ | CDC7 | O00311 | 6/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447097 | 0.80 | CDC7 (0.48) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL278830 | 0.79 | CDK2 (0.56) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL5258483 | 0.76 | CDC7 (0.46) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL4031036 | 0.75 | CDK2 (0.45) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL30310198 | 0.75 | CDC7 (0.46) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL4030180 | 0.70 | CDK2 (0.46) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL4022128 | 0.70 | CDK2 (0.47) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL6596532 | 0.68 | DYRK1A (0.45) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL5109260 | 0.68 | MAPK14 (0.49) | CDK2CDC7CDK9DYRK3CCNT1 | |
| SCHEMBL4020333 | 0.68 | CDC7 (0.53) | CDK2CDC7CDK9DYRK3CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| EP-1828183-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006064251-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | CDK2 4/4885CDC7 90/4885CDK9 10/4885 |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | CDK2 23/4885CDC7 175/4885CDK9 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.